Accumulate Sun Pharma on declines: Nilesh Shah

Nilesh Shah, MD & CEO at Envision Capital told CNBC-TV18, "There could be some more downside in Sun Pharmaceutical Industries because I clearly believe market is a slave of growth. Sun Pharma continues to be an excellent company, structurally it is in a sweet spot but the strategy which they have been implementing for years will continue to unfold and will continue to deliver growth for the company. But the issue that they are going through right now is more temporary in nature which could probably last for a two-three quarters.""I clearly believe that if you have a multi-year horizon, may be this is a good opportunity to buy now and then use any further declines to keep accumulating this stock for the long-term," he said.